2 drug(s) with this reaction
1,769 total reports
Femur Fracture has been reported as an adverse reaction across 2 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,769 adverse event reports mention femur fracture in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with femur fracture, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have femur fracture listed in their FDA adverse event reports, sorted by report count:
In addition to femur fracture, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
2 drug(s) manufactured by Amgen Inc have femur fracture listed in their FDA adverse event reports: DENOSUMAB, ROMOSOZUMAB-AQQG.
There are a combined 1,769 reports of femur fracture across 2 Amgen Inc drug(s) in the FDA adverse event database.